For research use only. Not for therapeutic Use.
Tesmilifene fumarate (DPPE fumarate), an H1C receptor antagonist, potentiates a wide range of cytotoxics and even to offer some protection of normal cells[1][2].
Tesmilifene may modulate the effects of 12(S)HETE in cancer cells, and indirectly, influence the susceptibility of cellular DNA to chemotherapy[1].
Tesmilifene (DPPE, 20 mg/kg (s.c.) and 20 μg (icv in 5 μL)) potentiated seizures induced by both convulsants[2].
| Catalog Number | I010292 |
| CAS Number | 1185241-83-1 |
| Synonyms | 2-(4-benzylphenoxy)-N,N-diethylethanamine;(E)-but-2-enedioic acid |
| Molecular Formula | C23H29NO5 |
| Purity | ≥95% |
| InChI | InChI=1S/C19H25NO.C4H4O4/c1-3-20(4-2)14-15-21-19-12-10-18(11-13-19)16-17-8-6-5-7-9-17;5-3(6)1-2-4(7)8/h5-13H,3-4,14-16H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+ |
| InChIKey | ZOOMDYHTGZSGDD-WLHGVMLRSA-N |
| SMILES | CCN(CC)CCOC1=CC=C(C=C1)CC2=CC=CC=C2.C(=CC(=O)O)C(=O)O |
| Reference | [1]. Mark Vincent, et al. Tesmilifene may enhance breast cancer chemotherapy by killing a clone of aggressive, multi-drug resistant cells through its action on the p-glycoprotein pump. Med Hypotheses. 2006;66(4):715-31. [2]. G Sturman, et al. Modulation of the intracellular and H3-histamine receptors and chemically-induced seizures in mice Agents Actions. 1994 Jun;41 Spec No:C68-9. |
